Holen Sie sich die Stockscreener-App
2.7108
0.33%
-0.0092
Eledon Pharmaceuticals Inc Aktie (ELDN) Neueste Nachrichten
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma rises on FDA orphan status for lead asset - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
Eledon Pharmaceuticals (ELDN) Enters Research Partnership to Com - GuruFocus
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - TradingView
Stem-cell islets plus immune drug: NewcelX, Eledon target Type 1 diabetes - Stock Titan
ELDN SEC FilingsEledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - MSN
Jobs Data: Is Eledon Pharmaceuticals Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - Naître et grandir
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - Sahm
Targets Report: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Institutional & Risk Controlled Swing Alerts - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Gainers: Whats Eledon Pharmaceuticals Incs historical returnBond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
ELDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What makes Eledon Pharmaceuticals Inc. stock attractive todayGlobal Markets & High Accuracy Trade Signal Alerts - mfd.ru
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Sahm
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Eledon Pharmaceuticals drops 10% on stock offering - MSN
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Up 3.6% – Should You Buy? - Defense World
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating - TipRanks
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Sahm
Eledon reports positive 24-month kidney transplant data for tegoprubart By Investing.com - Investing.com India
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Craig-Hallum Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating - 富途资讯
Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter Symposium - marketscreener.com
Eledon Pharmaceuticals (ELDN) to Reveal Promising Kidney Transpl - GuruFocus
Eledon reports positive 24-month kidney transplant data for tegoprubart - Investing.com
2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - stocktitan.net
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
What Caused Eledon Pharmaceuticals Stock (ELDN) to Drop 50% Today? - Intellectia AI
Patterns Watch: Is AVAH forming a double bottomWeekly Trend Recap & Smart Investment Allocation Tips - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts - Defense World
Buy Signal: Will Eledon Pharmaceuticals Inc stock deliver better than expected guidanceJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):